Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정지은 | - |
dc.date.accessioned | 2022-03-04T05:13:20Z | - |
dc.date.available | 2022-03-04T05:13:20Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.citation | JOURNAL OF PERSONALIZED MEDICINE, v. 11, NO 9, Page. 1-13 | en_US |
dc.identifier.issn | 20754426 | - |
dc.identifier.uri | https://www.mdpi.com/2075-4426/11/9/862 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/168791 | - |
dc.description.abstract | 23 subjects were carriers of SLCO1B1*1B and two subjects were included in the reference group with SLCO1B1*1A/*1A. Alternations of the splicing factor-binding site pattern caused by the given mutation were evaluated with the Human Splicing Finder (HSF) 3.1. Results: The subjects who carried SLCO1B1*1B showed a 2.3-fold higher clearance than those without the *1B haplotype. Mean C-max and AUC(inf) were reduced by 45% and 54%, respectively, in the SLCO1B1*1B genotype group compared to the reference group with the *1A/*1A genotype (p ˂ 0.01). The carriers of the rs4149153 T allele of SLCO1B3 had a 27% lower mean C-max and a 1.5-fold higher Vd compared to homozygotic CC carriers (p ˂ 0.05). In a combined analysis of SLCO1B1 and SLCO1B3, subjects not carrying SLCO1B1 *1B and carrying SLCO1B3 rs4149153 T allele showed a 1.6-fold higher clearance than those with the other genotypes, whereas mean C-max and AUC(last) were reduced by 35% and 42%, respectively (p ˂ 0.05), in the subjects. HSF 3.1 analysis showed that rs4149153 could cause alterations of the acceptor splice site (TAAATACTAAAGAC to TAAATATTAAAGAC) with scoring change (from 72.57 to 71.92, difference = -0.9). Conclusion: It was found that plasma exposure to valsartan is significantly decreased in SLCO1B1*1B carriers and carriers of the rs4149153 T allele of SLCO1B3, possibly as a result of increased hepatic uptake. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.subject | valsartan | en_US |
dc.subject | SLCO1B1 | en_US |
dc.subject | SLCO1B3 | en_US |
dc.subject | Single nucleotide polymorphism | en_US |
dc.subject | pharmacokinetics | en_US |
dc.title | Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers | en_US |
dc.type | Article | en_US |
dc.relation.no | 9 | - |
dc.relation.volume | 11 | - |
dc.identifier.doi | https://doi.org/10.3390/jpm11090862 | - |
dc.relation.page | 1-13 | - |
dc.relation.journal | JOURNAL OF PERSONALIZED MEDICINE | - |
dc.contributor.googleauthor | Song, Gonjin | - |
dc.contributor.googleauthor | Chung, Jee-Eun | - |
dc.contributor.googleauthor | Yee, Jeong | - |
dc.contributor.googleauthor | Lee, Kyung-Eun | - |
dc.contributor.googleauthor | Park, Kyungsoo | - |
dc.contributor.googleauthor | Gwak, Hye-Sun | - |
dc.relation.code | 2021009025 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | jechung | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.